Yellow fever virus: Difference between revisions

From IDWiki
No edit summary
No edit summary
Line 1: Line 1:
== Background ==
+
==Background==
   
=== Microbiology ===
+
===Microbiology===
   
* RNA virus and member of the [[Flaviviridae]] family
+
*RNA virus and member of the [[Flaviviridae]] family
   
== Prevention ==
+
=== Epidemiology ===
   
  +
* Worldwide, about 200,000 cases and 30,000 deaths annually
* Vaccination can cause [[Yellow fever vaccine-associated neurotropic disease|YF vaccine-associated neurotropic disease]] and [[Yellow fever vaccine-associated viscerotropic disease|YF vaccine-associated viscerotropic disease]], primarily in older people
 
  +
  +
== Clinical Manifestations ==
  +
  +
* Spectrum of illness from asymptomatic to fatal
  +
* Acute illness starts with fever, chills, headache, backache, myalgias, arthralgias, nausea, vomiting, photophobia, mild jaundice, and epigastric pain
  +
* After the acute illness subsides, about 85% of infections are resolved, and 15% progress
  +
* In those who progress, a brief remission of hours to days is followed by return of symptoms with progression to renal failure, hemorrhage, and thrombocytopenia
  +
  +
=== Vaccine-Related Disease ===
  +
  +
* [[Yellow fever vaccine-associated neurotropic disease]], which includes [[meningoencephalitis]], [[Guillain-Barré syndrome]], and acute bulbar palsy
  +
* [[Yellow fever vaccine-associated viscerotropic disease]], which causes multi-organ failure similar to wildtype virus
  +
  +
{| class="wikitable"
  +
!
  +
![[Yellow fever vaccine-associated neurotropic disease|YEL-AND]]
  +
![[Yellow fever vaccine-associated viscerotropic disease|YEL-AVD]]
  +
|-
  +
|Incubation period
  +
|7 to 21 days
  +
|2 to 5 days
  +
|-
  +
|Rate
  +
|0.8 per 100,000 doses
  +
|1 per 100,000 doses
  +
|-
  +
|Risk factors
  +
|age <6 months
  +
age >60-70 years
  +
|age >60 years
  +
thymus disease
  +
|-
  +
|Prognosis
  +
|full recovery
  +
|65% mortality
  +
|}
  +
  +
== Management ==
  +
  +
* Supportive care
  +
  +
==Prevention==
  +
  +
*A live attenuated vaccine strain is available
  +
*Contraindications
  +
**Allergy to any component of the vaccine
  +
**Infants less than 6 to 9 months of age, due to the high risk of [[Yellow fever vaccine-associated neurotropic disease|neurotropic disease]] following immunization
  +
**People age 60 years and older, due to the high risk of adverse events following immunization
  +
***Booster doses may stll be given, if indicated
  +
**Pregnancy and breastfeeding
  +
**Thymus disease, including [[thymoma]], [[thymectomy]], and [[myasthenia gravis]], given the high risk of [[Yellow fever vaccine-associated viscerotropic disease|viscerotropic disease]]
  +
**Moderate or severe acute illness
 
*Vaccination can cause [[Yellow fever vaccine-associated neurotropic disease|YF vaccine-associated neurotropic disease]] and [[Yellow fever vaccine-associated viscerotropic disease|YF vaccine-associated viscerotropic disease]]
   
 
[[Category:Flaviviridae]]
 
[[Category:Flaviviridae]]

Revision as of 20:24, 16 September 2020

Background

Microbiology

Epidemiology

  • Worldwide, about 200,000 cases and 30,000 deaths annually

Clinical Manifestations

  • Spectrum of illness from asymptomatic to fatal
  • Acute illness starts with fever, chills, headache, backache, myalgias, arthralgias, nausea, vomiting, photophobia, mild jaundice, and epigastric pain
  • After the acute illness subsides, about 85% of infections are resolved, and 15% progress
  • In those who progress, a brief remission of hours to days is followed by return of symptoms with progression to renal failure, hemorrhage, and thrombocytopenia

Vaccine-Related Disease

YEL-AND YEL-AVD
Incubation period 7 to 21 days 2 to 5 days
Rate 0.8 per 100,000 doses 1 per 100,000 doses
Risk factors age <6 months

age >60-70 years

age >60 years

thymus disease

Prognosis full recovery 65% mortality

Management

  • Supportive care

Prevention